<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20779">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02836379</url>
  </required_header>
  <id_info>
    <org_study_id>ANG-DOL-2016-01</org_study_id>
    <nct_id>NCT02836379</nct_id>
  </id_info>
  <brief_title>Quality of Life Study in Patients With Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent</brief_title>
  <acronym>CAVIDIOR</acronym>
  <official_title>Quality of Life Study in Patients With Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angelini Farmacéutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Angelini Farmacéutica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the context of radiotherapy, control of breakthrough pain represents a special challenge.
      Patients undergoing radiotherapy may experience different situations of pain that may be due
      to the need to remain immobilized during radiotherapy session, the need to wear an
      immobilization mask (head and neck cancer), the odynophagia caused by mucositis, defecation
      after the development of proctitis, or sudden pain during the night causing sleep
      disturbances.

      In a survey conducted in radiation oncology services more than half of patients treated with
      radiotherapy experienced pain, and 39% of patients reported that their pain was not treated
      properly. This situation may increase the patient's anxiety, dissatisfaction with treatment,
      affect their quality of life and can even come to refuse radiotherapy treatment.

      This post-authorization observational study will assess the quality of life of cancer
      patients with breakthrough cancer pain treated in radiotherapy services in Spanish
      hospitals.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in quality of life according SF-12 questionnaire</measure>
    <time_frame>Baseline and 4-6 weeks (estimated end of radiotherapy treatment)</time_frame>
    <description>Change in punctuation of the SF-12 questionnaire between end of radiotherapy treatment and baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with neuropathic, visceral, somatic and mixed pain</measure>
    <time_frame>Baseline (the day that patient sign the informed consent form)</time_frame>
    <description>Percentage of patients with neuropathic, visceral, somatic and mixed pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbidities associated with patients</measure>
    <time_frame>Baseline (the day that patient sign the informed consent form)</time_frame>
    <description>Percentage of patients with each comorbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to relief of breakthrough pain</measure>
    <time_frame>Up to 6 weeks, from date of inclusion until the end of radiotherapy treatment</time_frame>
    <description>Time from the start of the episode until the relief of breakthrough pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of the episodes of breakthrough pain</measure>
    <time_frame>Up to 6 weeks, from date of inclusion until the end of radiotherapy treatment</time_frame>
    <description>Time from the start of the episode until the pain ends</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global improvement</measure>
    <time_frame>4-6 weeks (estimated end of radiotherapy treatment)</time_frame>
    <description>Number of patients indicating each of the possible answers of the Clinical Global Impression of improvement scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global improvement</measure>
    <time_frame>4-6 weeks (estimated end of radiotherapy treatment)</time_frame>
    <description>Number of patients indicating each of the possible answers of the Patient Global Impression of improvement scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in assessment (percentage) of family claudication</measure>
    <time_frame>Baseline and 4-6 weeks (estimated end of radiotherapy treatment)</time_frame>
    <description>Difference in percentage of patients with punctuation ≥ 17 points at end of radiotherapy treatment and baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean Intensity of breakthrough cancer pain at each study visit</measure>
    <time_frame>Up to 6 weeks, from date of inclusion until the end of radiotherapy treatment</time_frame>
    <description>Intensity of breakthrough cancer pain assessed with a Visual Analog Scale (VAS). VAS will be compared at each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MOS Sleep Scale scores</measure>
    <time_frame>Baseline and 4-6 weeks (estimated end of radiotherapy treatment)</time_frame>
    <description>Change in MOS Sleep Scale scores between end of radiotherapy treatment and baseline</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breakthrough Pain</condition>
  <arm_group>
    <arm_group_label>Breakthrough Cancer Pain</arm_group_label>
    <description>No intervention (Non-interventional study)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Breakthrough Cancer Pain</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with breakthrough cancer pain treated in Radiation Oncology services with
        palliative intent will be included
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt; 18 years

          -  Cancer Patients

          -  Patients attended in radiation oncology consultations with palliative intent

          -  Life expectancy &gt; 6 months

          -  Written informed consent

          -  Patients with baseline controlled cancer pain with opioids who are diagnosed of
             breakthrough cancer pain by Davies algorithm

        Exclusion Criteria:

          -  Untreated patients with opioids for baseline pain

          -  Patients who are not opioid tolerant

          -  Serious psychiatric disorder or any disease or condition that prevents the collection
             of data

          -  Patients with evidence of opioid addiction or history of drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Mañas, MD</last_name>
    <role>Study Director</role>
    <affiliation>IMONCOLOGY, Hospital la Milagrosa. Madrid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan L Sanz</last_name>
    <phone>0034 918166804</phone>
    <phone_ext>103</phone_ext>
    <email>juanluis.sanz@apices.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Moreno</last_name>
    <phone>0034 918166804</phone>
    <phone_ext>100</phone_ext>
    <email>ana.moreno@apices.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Gómez Caamaño, MD</last_name>
      <phone>981951410</phone>
      <email>Antonio.Gomez.Caamano@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Antonio Gómez Caamaño, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de galicia</name>
      <address>
        <city>A Coruña</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de l'Esparnça</name>
      <address>
        <city>Barcelona</city>
        <zip>08024</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Reig, MD</last_name>
      <email>91793@parcdesalutmar.cat</email>
    </contact>
    <investigator>
      <last_name>Ana Reig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorena Díez, MD</last_name>
      <phone>+34 657104143</phone>
      <email>ldiez@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Lorena Díez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosa Morera, MD</last_name>
      <phone>+34 656379813</phone>
      <email>rosamaria.morera@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Rosa Morera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Inmaculada Fortes, MD</last_name>
      <phone>646968634</phone>
      <email>inmafor55@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Inmaculada Fortes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vergen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Illescas, MD</last_name>
      <phone>+34 635375595</phone>
      <email>aillesva@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ana Illescas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 21, 2016</lastchanged_date>
  <firstreceived_date>July 11, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breakthrough Cancer Pain</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breakthrough Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
